Aducanumab

Lecanemab vs aducanumab

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Future direction for anti-amyloid immunotherapies

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Lowering blood pressure as a treatment for VCID

Impact of Alzheimer’s disease treatments on apathy

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Is amyloid lowering still a valid approach in Alzheimer’s disease?

Potential of anti-amyloid drugs for treating Alzheimer’s disease

Important developments in dementia: biomarkers & clinical trials

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Development of a new anti-amyloid antibody PMN310 for the treatment of Alzheimer’s disease

Discussing the future of aducanumab in dementia care at AAN 2022

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab